For Q4 2025, Vir reported total revenue of 64070000 primarily from license revenue, with a net loss of 42923000, reflecting reduced operating expenses year over year and a strengthened cash position of 781600000 in cash and investments.

Vir Biotechnology reported a net loss of $120.965 million for Q1 2025, compared to a net loss of $65.276 million in Q1 2024. Total revenues decreased significantly to $3.032 million from $56.376 million in the prior year, primarily due to the expiration of GSK's rights. The company maintains a strong financial position with approximately $1.02 billion in cash and investments, providing a runway into mid-2027.

Vir Biotechnology reported a net loss of $(104.6) million for Q4 2024, an improvement from $(116.0) million in Q4 2023. Total revenues for the quarter were $12.4 million, down from $16.8 million in the prior year. The company ended the year with $1.10 billion in cash, cash equivalents, and investments, providing a cash runway into mid-2027.

Vir Biotechnology reported a net loss of $213.7 million for the third quarter of 2024. The company closed an exclusive worldwide license agreement with Sanofi for three clinical-stage masked T-cell engagers and is focusing on infectious diseases and oncology. Jason O’Byrne was appointed as the new CFO.

Vir Biotechnology reported a net loss of $138.4 million for the second quarter of 2024. The company is strategically restructuring to focus on hepatitis programs and has signed an exclusive license agreement with Sanofi. As of June 30, 2024, the company had $1.43 billion in cash, cash equivalents and investments.

Vir Biotechnology reported a net loss of $65.3 million, or $(0.48) per share, for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $1.51 billion as of March 31, 2024. Total revenues for the quarter were $56.4 million, compared to $63.0 million for the same period in 2023.

Vir Biotechnology reported a net loss of $116 million for the fourth quarter of 2023, with total revenues of $16.8 million. The company's cash, cash equivalents, and investments stood at $1.63 billion as of December 31, 2023. The company is focusing its capital allocation on programs with the highest potential for patient impact and value creation.

Vir Biotechnology reported a net loss of $163.4 million for the third quarter of 2023, with total revenues of $2.6 million. The company had $1.7 billion in cash, cash equivalents, and investments as of September 30, 2023. They also made a $67.0 million payment to GSK for excess sotrovimab supply and manufacturing capacity.

Vir Biotechnology reported a net loss of $194.8 million for the second quarter of 2023. The company is prioritizing its monoclonal antibody platform and advancing its pipeline programs, with data readouts expected in Q4 for chronic hepatitis B and hepatitis delta programs. Vir had $1.9 billion in cash, cash equivalents, and investments as of June 30, 2023.

Vir Biotechnology reported a decrease in revenue to $63.0 million compared to $1.2 billion for the same period in 2022, primarily due to lower sotrovimab sales. The company's net loss was $140.9 million, or $1.06 per share. They had $2.3 billion in cash, cash equivalents, and investments as of March 31, 2023.

Vir Biotechnology reported Q4 2022 revenues of $49.4 million and a net loss of $101.6 million. The company delivered approximately 63,000 sotrovimab doses and recognized $26.4 million of grant revenue in connection with the BARDA agreement.

Vir Biotechnology reported a strong third quarter with total revenues of $374.6 million, driven by collaboration revenue from sotrovimab sales and a BARDA contract. The company is advancing its pipeline with multiple Phase 2 data readouts expected in 2023 and has a strong balance sheet with approximately $2.7 billion in cash and investments.

Vir Biotechnology reported a net loss of $76.5 million for the second quarter of 2022, with revenues totaling ($40.6 million). The company is shifting its strategy to focus on long-term control of COVID-19 and advancing its pipeline in hepatitis B, hepatitis D, and influenza A. Vir's cash, cash equivalents, investments, and profit-share payments from GSK are expected to fund operations for up to five years.

Vir Biotechnology reported $1.2 billion of sotrovimab collaboration revenue in the first quarter of 2022 and has over $2.5 billion in cash, cash equivalents, investments and collaboration receivables. The company shared encouraging initial data from its Phase 2 MARCH trial evaluating hepatitis B functional cure.

Vir Biotechnology reported total revenues of $812.7 million for the quarter ended December 31, 2021, primarily driven by collaboration revenue from sotrovimab sales. Net income for the quarter was $525.3 million, or $3.92 per share diluted.

Vir Biotechnology reported a net income of $110.4 million for the third quarter of 2021, primarily driven by collaboration revenue from sotrovimab sales and an unrealized gain from equity investment in Brii Biosciences. The company made significant progress in increasing global patient access to sotrovimab and is advancing its pipeline with multiple clinical trials and data readouts expected in the fourth quarter.

Vir Biotechnology reported a net income of $61.8 million for the second quarter of 2021, a significant increase compared to a net loss of $31.2 million for the same period in 2020. The increase was primarily due to revenue recognition related to the license granted to GSK under the Company’s 2021 GSK agreement. Sotrovimab is now available for patients who become ill with COVID-19 and are at high risk for hospitalization.

Vir Biotechnology reported total revenues of $2.0 million and a net loss of $168.9 million for the first quarter ended March 31, 2021. The company highlighted progress in its COVID-19 and hepatitis B programs, including the Phase 3 trial results of VIR-7831 and collaborations with Gilead and GSK.

Vir Biotechnology reported fourth-quarter revenue of $1.7 million, primarily due to the timing of research activities under the HIV and TB grants with the Bill & Melinda Gates Foundation. The company's net loss for the quarter was $105.6 million, or $0.83 per share. As of December 31, 2020, the company had approximately $736.9 million in cash, cash equivalents and investments.

Vir Biotechnology reported $1.9 million in revenues for the third quarter ended September 30, 2020, compared to $1.4 million for the same period in 2019. Net loss for the quarter was $84.6 million, or $0.67 per share, compared to a net loss of $48.3 million, or $4.60 per share for the same period in 2019.

Vir Biotechnology reported a net loss of $63.8 million for the fourth quarter of 2019, with total revenues of $1.0 million and research and development expenses of $52.9 million. The company highlighted its progress in expanding its clinical and preclinical pipeline and collaborations for COVID-19 therapies.